Q-omics provides the consensus-scored RBFOX1 profile across patient tissues and cancer cell-line models. RBFOX1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RBFOX1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RBFOX1 protein abundance shows 13,368 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where RBFOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBFOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBFOX1 survival associations across molecular data types. RBFOX1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBFOX1 RNA expression–survival associations across cancer types. High RBFOX1 expression shows unfavorable associations in KIRC, HNSC and LIHC, but favorable associations in LUAD, KIRP and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for RBFOX1 RNA expression.
This table summarizes RBFOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBFOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBFOX1 shows lower tumor expression in KIRC, KIRP, HNSC, READ, KICH and UCEC. The KIRC box plot shows higher RBFOX1 RNA expression in normal versus tumor tissue (log2 FC = −0.318, t-test p < 0.001).
This table shows molecular features associated with RBFOX1 in patient tissues and cancer cell lines. In patient samples, RBFOX1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBFOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
